Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.

Stephanie SchwartzNidhi PatelTyler LongmirePushpa JayaramanXiaomo JiangHongbo LuLisa BakerJanelle VelezRadha RameshAnne-Sophie WavreilleMelanie VerneretHong FanTiancen HuFangmin XuJohn TaraszkaMarc PelletierJoy MiyashiroMikael RinneGlenn DranoffCatherine Sabatos-PeytonViviana Cremasco

Published in: Immunotherapy advances (2022)

Taken together, our results support both direct anti-leukemic effects and immune-mediated modulation by sabatolimab, reinforcing the notion that sabatolimab represents a novel immunotherapy with immuno-myeloid activity, holding promise for the treatment of myeloid cell neoplasms.

Keyphrases

acute myeloid leukemia
dendritic cells
bone marrow
single cell
big data
stem cells
machine learning
deep learning
artificial intelligence